Sweden
# |
Name |
EBITDA |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 2.06 B
|
Dec. 31, 2023 | USD 26.00 | 1.16% |
|
Sweden |
|
2 |
USD 714.00 M
|
Dec. 31, 2023 | USD 28.64 | 0.87% |
|
Sweden |
|
3 |
USD 621.02 M
|
Dec. 31, 2023 | USD 28.08 | 0.23% |
|
Sweden |
|
4 |
USD 585.19 M
|
Dec. 31, 2023 | USD 16.63 | 0.49% |
|
Sweden |
|
5 |
USD 301.33 M
|
Dec. 31, 2023 | USD 4.58 | 1.67% |
|
Sweden |
|
6 |
USD 297.84 M
|
April 30, 2024 | USD 5.39 | -0.39% |
|
Sweden |
|
7 |
USD 284.11 M
|
Dec. 31, 2023 | USD 17.18 | 2.59% |
|
Sweden |
|
8 |
USD 225.13 M
|
Dec. 31, 2023 | USD 8.10 | 1.52% |
|
Sweden |
|
9 |
USD 193.55 M
|
Dec. 31, 2023 | USD 3.30 | 3.88% |
|
Sweden |
|
10 |
USD 152.59 M
|
Dec. 31, 2023 | USD 12.08 | 1.50% |
|
Sweden |
|
11 |
USD 76.36 M
|
Dec. 31, 2023 | USD 3.41 | 3.24% |
|
Sweden |
|
12 |
USD 55.66 M
|
April 30, 2024 | USD 22.17 | -0.20% |
|
Sweden |
|
13 |
USD 55.52 M
|
Dec. 31, 2023 | USD 51.72 | -0.10% |
|
Sweden |
|
14 |
USD 48.85 M
|
Dec. 31, 2023 | USD 9.75 | -0.95% |
|
Sweden |
|
15 |
USD 42.64 M
|
Dec. 31, 2023 | USD 11.98 | -2.51% |
|
Sweden |
|
16 |
USD 41.59 M
|
Dec. 31, 2023 | USD 0.28 | 0.36% |
|
Sweden |
|
17 |
USD 40.07 M
|
Dec. 31, 2023 | USD 20.58 | 0.68% |
|
Sweden |
|
18 |
USD 29.15 M
|
Dec. 31, 2023 | USD 17.87 | 3.09% |
|
Sweden |
|
19 |
USD 22.66 M
|
Dec. 31, 2023 | USD 14.61 | 2.17% |
|
Sweden |
|
20 |
USD 21.27 M
|
Dec. 31, 2023 | USD 0.53 | -3.21% |
|
Sweden |
|
21 |
USD 20.46 M
|
Dec. 31, 2023 | USD 18.76 | 3.89% |
|
Sweden |
|
22 |
USD 16.92 M
|
Dec. 31, 2023 | USD 5.68 | 4.11% |
|
Sweden |
|
23 |
USD 14.62 M
|
Dec. 31, 2023 | USD 2.59 | 1.03% |
|
Sweden |
|
24 |
USD 12.49 M
|
Dec. 31, 2023 | USD 42.37 | 0.78% |
|
Sweden |
|
25 |
USD 11.41 M
|
Dec. 31, 2023 | USD 31.10 | 0.68% |
|
Sweden |
|
26 |
USD 6.51 M
|
Dec. 31, 2023 | USD 0.89 | 14.73% |
|
Sweden |
|
27 |
USD 6.37 M
|
Dec. 31, 2023 | USD 2.09 | -2.04% |
|
Sweden |
|
28 |
USD 6.32 M
|
Dec. 31, 2023 | USD 3.33 | 0.41% |
|
Sweden |
|
29 |
USD 5.53 M
|
Dec. 31, 2023 | USD 19.07 | 4.08% |
|
Sweden |
|
30 |
USD 4.83 M
|
Dec. 31, 2023 | USD 2.57 | -0.02% |
|
Sweden |
|
31 |
USD 3.10 M
|
Dec. 31, 2023 | USD 3.31 | 2.33% |
|
Sweden |
|
32 |
USD 3.00 M
|
Dec. 31, 2023 | USD 4.99 | 0.68% |
|
Sweden |
|
33 |
USD 2.86 M
|
Dec. 31, 2023 | USD 32.97 | -0.61% |
|
Sweden |
|
34 |
USD 2.85 M
|
Dec. 31, 2023 | USD 2.19 | 0.18% |
|
Sweden |
|
35 |
USD 1.14 M
|
Dec. 31, 2023 | USD 4.07 | -5.72% |
|
Sweden |
|
36 |
USD 792.92 K
|
April 30, 2024 | USD 1.60 | -0.43% |
|
Sweden |
|
37 |
USD 717.15 K
|
Dec. 31, 2023 | USD 0.45 | 23.08% |
|
Sweden |
|
38 |
USD 603.35 K
|
Dec. 31, 2023 | USD 0.97 | -2.02% |
|
Sweden |
|
39 |
USD 177.07 K
|
Dec. 31, 2023 | USD 0.23 | -0.87% |
|
Sweden |
|
40 |
USD 4.15 K
|
Dec. 31, 2023 | USD 0.29 | 0.68% |
|
Sweden |
|
41 |
USD 197.40
|
Dec. 31, 2023 | USD 0.13 | -6.51% |
|
Sweden |
|
42 |
USD -166.41 K
|
Dec. 31, 2023 | USD 0.84 | -0.17% |
|
Sweden |
|
43 |
USD -205.30 K
|
Dec. 31, 2023 | USD 0.14 | 1.34% |
|
Sweden |
|
44 |
USD -291.22 K
|
Dec. 31, 2023 | USD 0.09 | 1.68% |
|
Sweden |
|
45 |
USD -363.61 K
|
Dec. 31, 2023 | USD 1.88 | 0.68% |
|
Sweden |
|
46 |
USD -869.79 K
|
Dec. 31, 2023 | USD 0.39 | 2.53% |
|
Sweden |
|
47 |
USD -987.91 K
|
Dec. 31, 2023 | USD 0.11 | 1.51% |
|
Sweden |
|
48 |
USD -1.20 M
|
Aug. 31, 2024 | USD 0.30 | -1.39% |
|
Sweden |
|
49 |
USD -1.21 M
|
April 30, 2024 | USD 0.14 | 0.68% |
|
Sweden |
|
50 |
USD -1.29 M
|
Dec. 31, 2023 | USD 1.01 | -1.50% |
|
Sweden |
The Health Care company in Sweden with the highest EBITDA is Essity AB (publ) (Stockholm Stock Exchange: ESSITY-B.ST) at USD 2.06 B.
The Health Care company in Sweden with the lowest EBITDA is Vitrolife AB (publ) (Stockholm Stock Exchange: VITR.ST) at USD -314.36 M.
The top 10 Health Care companies in Sweden by EBITDA are Essity AB (publ), Swedish Orphan Biovitrum AB (publ), Lifco AB (publ), Getinge AB (publ), Attendo AB (publ), Elekta AB (publ), Medicover AB (publ), Ambea AB (publ), Arjo AB (publ) and AddLife AB (publ).
The bottom 10 Health Care companies in Sweden by EBITDA are Vitrolife AB (publ), Hansa Biopharma AB (publ), Egetis Therapeutics AB (publ), Vicore Pharma Holding AB (publ), BioInvent International AB (publ), Cantargia AB (publ), Oncopeptides AB (publ), SynAct Pharma AB, IRLAB Therapeutics AB (publ) and Xspray Pharma AB (publ).